Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma
Restricted accessResearch articleFirst published online November, 2014
Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma
The introduction of agents targeting vascular endothelial grow factors has radically changed the approach to metastatic renal cell carcinoma; however, cure is not within definitive reach. In many cases, the tumor will progress several months after the start of first-line therapy and new lines of therapy are required. Pazopanib and sorafenib are two frequently used targeted agents, and no sound data are currently available for patients who relapsed after pazopanib. In this paper we illustrate the SOAP study, which was designed to evaluate the safety and efficacy of sorafenib in terms of progression free-survival in 44 patients treated in 10 Italian centers who had relapsed after first-line pazopanib. Standard treatment with sorafenib will be administered until disease progression or unacceptable toxicity. Secondary endpoints include the evaluation of overall survival, safety and quality of life. A subanalysis to evaluate toxicities as predictive factors has also been planned.
GarciaJ.A., RiniB.I.: Recent progress in the management of advanced renal cell carcinoma.CA Cancer J Clin, 57: 112–125, 2007.
2.
CoppinC., KollmannsbergerC., LeL., PorzsoltF., WiltT.J.: Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.BJU Int, 108: 1556–1563, 2011.
MichelM.S., VervenneW., De SantisM., Fischer Von WeikersthalL., GoebellP.J., LerchenmuellerJ., ZimmermannU., BosMMEM, FreierW., Schirrmacher-MemmelS., StaehlerM.D., PahernikS., LosM., SchenckM., FlörckenA., Van ArkelC., HauswaldK., IndorfM., GottsteinD., EichelbergC.: SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).J Clin Oncol, 32(Suppl 4): abstr 393, 2014.
6.
EscudierB., PortaC., BonoP., PowlesT., EisenT., SternbergC.N., GschwendJ.E., De GiorgiU., ParikhO., HawkinsR., SevinE., NégrierS., KhanS., DiazJ., RedhuS., MehmudF., CellaD.: Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study.J Clin Oncol, 32: 1412–1418, 2014.
7.
MotzerR.J., HutsonT.E., CellaD., ReevesJ., HawkinsR., GuoJ., NathanP., StaehlerM., de SouzaP., MerchanJ.R., BoletiE., FifeK., JinJ., JonesR., UemuraH., De GiorgiU., HarmenbergU., WangJ., SternbergC.N., DeenK., McCannL., HackshawM.D., CrescenzoR., PanditeL.N., ChoueiriT.K.: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.N Engl J Med, 369: 722–731, 2013.
8.
RexerH.: First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11).Urologe A, 51: 724–726, 2012.
9.
NCT 01613846: Phase III Sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma (SWITCH-II). Available at: http://clinicaltrials.gov/show/NCT01613846, 2014.
10.
CarmichaelC., YuhB.E., SunV., LauC., HsuJ., SaikiaJ., LiuX., WilsonT., FerrellB., PalS.K.: Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors.Clin Genitourin Cancer, 11: 149–154, 2013.
11.
RaoD., ButtZ., RosenbloomS., RobinsonDJr, Von RoennJ., KuzelT.M., CellaD.: A comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).J Pain Symptom Manage, 38: 291–298, 2009.
12.
MotzerR.J., EscudierB., OudardS., HutsonT.E., PortaC., BracardaS., GrünwaldV., ThompsonJ.A., FiglinR.A., HollaenderN., UrbanowitzG., BergW.J., KayA., LebwohlD., RavaudA.; RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.Lancet, 372: 449–456, 2008.
13.
ShahD.R., ShahR.R., MorganrothJ.: Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.Drug Saf, 36: 413–426, 2013.
